Literature DB >> 12013537

Breast cancer in the clinic: treatments past, treatments future.

G W Sledge1.   

Abstract

Therapeutic options for the patient with systemic breast cancer were long limited to either chemotherapy and hormonal therapy. While these therapies provide palliation for many patients with advanced disease, and occasionally cure the patient with micrometastatic disease, they are not optimal either with regard to toxicity or efficacy. This paper reviews the past of systemic therapy (chemotherapy and hormonal therapy), then discusses developing treatment strategies. These strategies include the recently introduced anti-HER-2 antibody trastuzumab, novel agents targeting other aspects of tumor growth mechanisms, as well as agents blocking angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12013537     DOI: 10.1023/a:1014747300739

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  54 in total

1.  Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.

Authors:  P Perrotte; T Matsumoto; K Inoue; H Kuniyasu; B Y Eve; D J Hicklin; R Radinsky; C P Dinney
Journal:  Clin Cancer Res       Date:  1999-02       Impact factor: 12.531

2.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

Authors:  M F Press; L Bernstein; P A Thomas; L F Meisner; J Y Zhou; Y Ma; G Hung; R A Robinson; C Harris; A El-Naggar; D J Slamon; R N Phillips; J S Ross; S R Wolman; K J Flom
Journal:  J Clin Oncol       Date:  1997-08       Impact factor: 44.544

3.  Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells.

Authors:  P O-charoenrat; P Rhys-Evans; H Modjtahedi; S A Eccles
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression.

Authors:  T L Yue; X Wang; C S Louden; S Gupta; K Pillarisetti; J L Gu; T K Hart; P G Lysko; G Z Feuerstein
Journal:  Mol Pharmacol       Date:  1997-06       Impact factor: 4.436

5.  Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.

Authors:  L Yen; X L You; A E Al Moustafa; G Batist; N E Hynes; S Mader; S Meloche; M A Alaoui-Jamali
Journal:  Oncogene       Date:  2000-07-20       Impact factor: 9.867

6.  The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.

Authors:  M D Pegram; R S Finn; K Arzoo; M Beryt; R J Pietras; D J Slamon
Journal:  Oncogene       Date:  1997-07-31       Impact factor: 9.867

7.  A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts.

Authors:  B Davies; P D Brown; N East; M J Crimmin; F R Balkwill
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

8.  Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression.

Authors:  M Toi; K Inada; H Suzuki; T Tominaga
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

9.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

Review 10.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.

Authors:  J G Klijn; P M Berns; P I Schmitz; J A Foekens
Journal:  Endocr Rev       Date:  1992-02       Impact factor: 19.871

View more
  3 in total

1.  The molecular genetics of breast cancer and targeted therapy.

Authors:  Rachel Suter; James A Marcum
Journal:  Biologics       Date:  2007-09

2.  Whole-body Imaging of Cell Death Provides a Systemic, Minimally Invasive, Dynamic, and Near-real Time Indicator for Chemotherapeutic Drug Toxicity.

Authors:  Steven E Johnson; Andrey Ugolkov; Chad R Haney; Gennadiy Bondarenko; Lin Li; Emily A Waters; Raymond Bergan; Andy Tran; Thomas V O'Halloran; Andrew Mazar; Ming Zhao
Journal:  Clin Cancer Res       Date:  2018-11-12       Impact factor: 13.801

3.  Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model.

Authors:  Yinghua Jin; Lingxiao Wei; Qiuying Jiang; Xiaowei Song; Chong Teng; Chengjuan Fan; Yanju Lv; Ying Liu; Weixi Shen; Li Li; Dayong Huang; Tao Xin
Journal:  Sci Rep       Date:  2018-10-26       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.